Westminster-based TriSalus acquires cancer drug candidate for up to $250M
WESTMINSTER and EMERYVILLE, California — TriSalus Life Sciences has purchased the development and sale rights of a breast cancer drug candidate from Dynavax Technologies Corp. (Nasdaq: DVAX) for what could total to be a $250 million deal as it pivots into clinical development.
In a statement Monday morning, the Westminster-based TriSalus said it will pay $5 million up front and $4 million at the end of the year for SD-101, a drug candidate that is thought to stimulate the immune system against various types of cancer and infectious diseases.
TriSalus recently rebranded itself from Surefire Medical…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
SaaviHome Franchise Co., Denver-based franchisor that provides smart-home technology-integration services, recently added new franchise locations…
-
Gloo Holdings Inc., a Boulder-based company that provides artificial intelligence and technology platforms for faith-based…
-
Boulder-based publishing technology company Sovrn Holdings Inc. has named Will Duckworth its chief technology officer.
-
BOULDER — Integral Partners LLC, a consulting firm that helps clients protect their identities and…
